Table 1. Selected demographic data and outcomes.
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
---|---|---|---|---|---|
Blood type | O− | A Rh− | B Rh− | O− | A Rh− |
Antibody | Anti-D, anti-C | Anti-D | Anti-D, anti-C | Anti-D, anti-C | Anti-D, anti-C, anti-E, anti-Fya |
History of IV drug use? | Yes | Yes | Yes | Yes | Yes |
Current drug use? | Methadone | Buprenorphine | Methadone | Buprenorphine | Illicit narcotics |
Hepatitis C infection? | No | Yes | No | Yes | Yes |
Antibodies in prior pregnancy? | No | No | No | No | NA |
Prior neonate/fetus with HDFN? | No | No | No | No | NA |
RhIG in previous pregnancies? | Yes, per patient report | Yes, per patient report | Yes, per patient report | Yes, per patient report | NA |
History of blood transfusion? | No | No | No | No | No |
Fetal/neonatal blood type and antigen status | O + , C antigen + | A Rh+ | O + , C antigen − | O + , C antigen + | O + , C antigen +, E and Fya antigen status undeterminable |
Pregnancy complications | Hydrops fetalis at 326/7 wk, opted for delivery | Hydrops fetalis at 290/7 wk | HDFN at 304/7 wk | HDFN at 326/7 wk, opted for delivery | HDFN at 190/7 wk |
Fetal/neonatal treatment | Neonatal exchange transfusions, IVIG therapy, and phototherapy | Seven intrauterine transfusions | Three intrauterine transfusions | Neonatal IVIG and phototherapy | Seven intrauterine transfusions |
Abbreviations: HDFN, hemolytic disease of the fetus and newborn; IV, intravenous; IVIG, intravenous immunoglobulin; RhIG, Rh immune globulin.